Why Mirum Pharmaceuticals, Inc. (MIRM) stock moved
Mirum Pharmaceuticals, Inc. (MIRM) shares fell 0.5% to $98.23 as of August 11, 2026, a slight decline from the prior close of $98.70. BestStocks flagged the session as a major change for MIRM. No single company-specific catalyst was confirmed during the move window. Below, we break down what changed for MIRM, why it matters for investors, how the stock reacted, and the catalysts on the calendar.
MIRM fell 0.5% to $98.23
MIRM fell 0.5% in its latest session, moving from $98.70 to $98.23.
What it means for Mirum Pharmaceuticals, Inc. investors
For Mirum Pharmaceuticals, Inc. investors, the recent signals add up to a bearish shift. On the constructive side: Mirum Pharmaceuticals, Inc. (MIRM) moved +5.49% from $95.41 to $100.65 on 2026-08-07; MIRM moved +4.28% from its $90.25 open to a $94.11 close on 2026-08-06. Weighing against that: Earnings missed expectations; Negative session, down 0.5%. Wall Street's consensus price target sits at $138.30, implying +40.8% upside from $98.23. BestStocks rates the overall signal quality weak (33/100). With earnings roughly 84 days out, the next report is the most likely near-term test of the move.
MIRM price reaction
MIRM last traded at $98.23, down $0.47 (-0.48%) from the previous close of $98.70. The session traded on 0.6× average volume (below avg), so participation was unremarkable. Over the past month the stock has ranged between $94.12 and $121.00, and it currently sits about 15% of the way up that band.
Bullish and bearish analyst opinions on Mirum Pharmaceuticals, Inc. (MIRM)
The consensus analyst price target on Mirum Pharmaceuticals, Inc. (MIRM) is $138.30, 40.8% above the recent $98.23. Over the past 90 days analysts logged 0 upgrades, 6 maintains, and 0 downgrades. Here is how the bullish and bearish cases on MIRM line up.
The bullish case
- Wall Street's consensus price target of $138.30 implies +40.8% upside from $98.23.
- The Street's most bullish target is $165.00 (+68.0%).
- Mirum Pharmaceuticals, Inc. (MIRM) moved +5.49% from $95.41 to $100.65 on 2026-08-07.
- MIRM moved +4.28% from its $90.25 open to a $94.11 close on 2026-08-06.
The bearish case
- Earnings missed expectations.
- Negative session, down 0.5%.
- Mirum Pharmaceuticals, Inc. (MIRM) moved -3.01% from $121.00 to $117.36 on 2026-07-16.
Weighing both sides, BestStocks' composite read of recent signals is bearish, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.
Analyst price targets and ratings are FMP consensus figures as of Aug 11, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.
Previous notable changes for MIRM
Frequently asked questions about MIRM
Why did Mirum Pharmaceuticals, Inc. (MIRM) stock move?
MIRM fell 0.5% to $98.23. No single company-specific catalyst was confirmed during the move window, and it looks technical.
How much did MIRM stock fall?
MIRM lost 0.48% ($0.47) versus the prior close of $98.70, last trading at $98.23 on 0.6× average volume.
When is Mirum Pharmaceuticals, Inc.'s next earnings date?
MIRM's next earnings report is estimated for 2026-11-03 — about 84 days away.
What is the analyst price target for MIRM?
The consensus analyst price target for MIRM is $138.30, about 40.8% above the current $98.23. Over the past 90 days, analysts recorded 0 upgrades, 6 maintains, and 0 downgrades.
How BestStocks tracks MIRM
This page is generated automatically by BestStocks' change-detection system after its price and volume cleared MIRM-specific materiality thresholds, triggering an evidence check. It draws on 20 tracked change events for MIRM, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of August 11, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.